EMP-012 is under clinical development by Empirico and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) ...
Arm Chief Executive Officer Rene Haas discusses the company’s role in the joint venture formed by SoftBank, OpenAI and Oracle to fund artificial intelligence infrastructure with an initial ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.